Navigation Links
Matthew Sarad to Reverse Aging and Cure Cancer
Date:9/11/2009

ases, such as macular degeneration, arteriosclerosis, osteoporosis, and other degenerative diseases that might be reversed by restoring telomere length.

According to Mr. Sarad, "This experiment is incredibly important. I think we now have a mixture of nanotechnology based gene therapy products that can result in what might be called significant 'organismal rejuvenation'. We have seen regeneration of human tissues in the laboratory. How far this technology can ultimately go is hard to say, but I am optimistic that this is the first step in what will be referred to historically as the moment the age-barrier was broken."

This research may also change the way that cancer is treated in the future. For example, Mr. Sarad's company licensed and improved a protein based anti-cancer therapeutic noted in studies by the University of Nebraska Medical Center to be non-toxic and to cause long-term remission in 80% of all cancer, including difficult to treat neuronal cancer. The Corporation was working on increasing the remission rate further by delivering other tumor suppressor proteins. One or more tumor suppressor genes is corrupted, silenced, or deleted in almost all cancer. This therapeutic drug is being studied today at the country's third largest hospital the Cleveland Clinic in the treatment of cancer and restenosis. The hospital is also studying some of the corporation's tissue regeneration technologies.

Mr. Sarad's career in biotechnology has not been without controversy. In 2008 he was sanctioned by the SEC for alleged securities violations made while taking his company public in 2006. The company, Telomolecular Corp., achieved public status but its shares were later deregistered.

"The mistake I made was being young, inexperienced, and excited about the prospects of our technologies," said Mr. Sarad. "I failed to disclose that our management was inexperienced engineering an IPO and this may have been mislea
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
10. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
11. Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering and developing innovative therapies primarily ... today announced that Dr. Pamela Pavco , ... the 23 rd World Congress of ... include in-depth presentations by world-class clinicians and/or ...
(Date:6/2/2015)... 2, 2015 MGB Biopharma ... resistance problem  MGB Biopharma, a biopharmaceutical ... to address the major global problem of antibiotic ... stable intravenous (IV) formulation of MGB-BP-3, designed for the ... The intravenous formulation of MGB-BP-3 is ...
(Date:6/1/2015)... , June 1, 2015 ... ) has announced the addition of the ... (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, ... Flow Cytometry), End Users - Global Forecast ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/1/2015)... June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... 31, 2015.  Biorem,s complete 2015 first quarter financial statements and MD&A ... Summary:Three-months ended March 31,(in CDN$,000 except per share data) ... , 1,974 Gross profit , 1,531 , ... earnings (loss) , 528 , (531) Basic earnings ...
Breaking Biology Technology:RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... Foundation for Angelman Syndrome Therapeutics (FAST) announces it will ... treatment for the rare genetic disorder, Angelman Syndrome (AS).  ... study will examine if the off label administration ... with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is ...
... Feb. 14, 2012  Milo Biotechnology will receive $250,000 ... assistance and some capital into early stage Northeast ... a therapy to increase muscle strength and improve ... Milo is the 61st company in JumpStart,s portfolio. ...
... Gen-Probe Incorporated (NASDAQ: GPRO ) today reported ... in the quarter grew 16%, to a new record of ... to a new high of $0.72. "Gen-Probe finished ... quarter while clinical diagnostics revenues continued their solid growth," said ...
Cached Biology Technology:Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 2Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 3JumpStart Invests $250,000 in Milo Biotechnology 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... Start-up awarded with an additional 100.000 Euros in financial ... opportunity to double the financial support through the execution ... 4th edition of the Building Global Innovators & continued ... 3rd edition of Building Global Innovators Venture Competition. The ...
... findings published in Pediatrics (Epub ahead of print) ... Disorders reveal that 70 percent of children with autism spectrum ... achieved phrase or fluent speech by age eight. This suggests ... at age four can be expected to make notable language ...
... perform only one job, but a new study by a ... recruit enzymes for other jobs to benefit medical fields and ... function in a cell, but many are capable of doing ... the beginning of a chemical reaction that they don,t ...
Cached Biology News:Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 2Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 3Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 4Speech emerges in children with autism and severe language delay at greater rate than thought 2Speech emerges in children with autism and severe language delay at greater rate than thought 3Promiscuous enzymes may be recruited to aid industry, medical fields 2
Values of steady state parameters for enzyme activities are determined....
... Proliferator-Activated Receptor-gamma (PPAR) is a member ... ligand-activated transcription factors that heterodimerize with ... involved in the regulation of glucose ... (TZD) class of anti-diabetic agents called ...
... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
Biology Products: